Compounded versions of popular drugs used for weight loss including Wegovy and Zepbound will soon no longer be available ...

In this podcast, Motley Fool analyst Karl Thiel joins host Ricky Mulvey to check in on the GLP-1 landscape. They discuss: How ...

New trial data showed CagriSema led to “superior” weight loss, but at a rate much less than original expectations of 25%.

Mounting competition in the sector and rising obesity have led the pharmaceutical company to start selling the drug directly ...

Novo Nordisk A/S (NVO) has slashed prices for its blockbuster weight-loss drug Wegovy as competition in the obesity drug market heats up, with ...

Compare ADHD medications Vyvanse (lisdexamfetamine) vs. Concerta (methylphenidate). Understand their similarities and ...

Drinking artificially sweetened beverages may reduce metformin’s effectiveness in young patients with obesity and prediabetes ...

When her mother suggested she try a weight-loss drug ... If the group not taking the drug had benefited from the more intensive coaching, he believes the comparison would be fairer.

Hims and Hers' stock fell over 19% in after-hours trading on Monday after its CEO said the company would no longer sell compounded versions of mega-hit weight loss drugs. "We will have to start ...

The number of drug-related fatalities in the UK linked to diabetes and weight loss medications has risen to 82, according to new data from the Medicines and Healthcare Products Regulatory Agency ...

Eli Lilly stock surges past $840, outperforming the S&P 500. Click here to learn why LLY stock is still undervalued and why now might be the time to invest.

Hims & Hers projects $725M in GLP-1 weight loss revenue for 2025, a 3.2x increase from 2024. Read why I upgrade HIMS stock from hold to strong buy.